Back to School: How biopharma can reboot drug development. Access exclusive analysis here

3TC nucleoside analog data

BCHXF (Laval, Québec) announced positive preliminary results of two North American Phase II/III trials involving 618 patients taking 3TC in combination with AZT. The company reported a 23-24 percent dropout rate for the trials, attributing dropouts to adverse publicity generated by the FIAU disaster. The company had previously reported data

Read the full 505 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE